Status: Recruiting
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
The primary objective of this study is to evaluate the efficacy and safety of Ensartinib in advanced ALK-positive non-small cell lung cancer, and the mechanisms of population pharmacokinetics and resistance to Ensartinib.
Participants needed: 490
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Peking Union Medical College HospitalUpdated: Aug 11, 2022Locations: 1
Eligibility criteria
Histologically or cytologically confirmed stage III b or IV NSCLC, according to... [+6]